Author

K.-J. Cho

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Naji· 2 shared H. Liang· 2 shared J. F. Hancock· 2 shared Y. Zhou· 2 shared A. A. Gorfe· 1 shared A. Gorfe· 1 shared A. K. Gupta· 1 shared C. V. Pagba· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

A. Naji

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MTMR regulates KRAS function by controlling plasma membrane levels of phospholipids

T. Lange, A. Naji, R. van der Hoeven, H. Liang, Y. Zhou, G. R. Hammond, J. F. Hancock, K.-J. Cho

The paper identifies MTMR proteins as regulators of KRAS function by controlling plasma membrane phospholipid levels, specifically PI4P and PtdSer.

bioRxiv · Jan 22, 2024Cell Biology

A new ferrocene derivative blocks KRAS localization and function by oxidative modification at His95.

K. M. Rehl, J. Selvakumar, D. Hoang, K. Arumugam, A. Gorfe, K.-J. Cho

This study shows a ferrocene derivative inhibits K-Ras function by oxidative modification at His95, blocking its membrane binding and signaling in cancer cells.

bioRxiv · Mar 28, 2023 · PreprintCell Biology

Discovery of allosteric non-covalent KRAS inhibitors that bind with sub-micromolar affinity and disrupt effector binding

M. J. McCarthy, C. V. Pagba, P. Prakash, A. Naji, D. van der Hoeven, H. Liang, A. K. Gupta, Y. Zhou, K.-J. Cho, J. F. Hancock, A. A. Gorfe

This study identifies a pyrazolopyrimidine-based allosteric KRAS inhibitor with sub-micromolar affinity that disrupts effector binding and inhibits cancer cell growth.

bioRxiv · Oct 11, 2018Biochemistry

K.-J. Cho · henhao